Business | 2010.03.16
Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 PromotesT Cell Viability, Trafficking, and Functionality While Improving Survival in Sepsis
PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival. Sepsis, a highly lethal disorder which occurs during severe overwhelming inf
For more information, please visit
http://www.businesswire.com/news/home/20100316005849/en
